Form 4: Drugs Made In America Acquisition Corp. Director Acquires 100,000 Ordinary Shares

Myron W. Shulgan, a director of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares from the Issuer's sponsor for no consideration on January 29, 2025.

Summary

• On January 29, 2025, Myron W. Shulgan, a director of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares.
• The shares were acquired from Drugs Made In America Acquisition LLC, the Issuer's sponsor.
• The acquisition was made for no consideration.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, and the transaction itself doesn't inherently indicate positive or negative sentiment. It's a neutral disclosure of information.

Industry Context

This Form 4 filing is a routine disclosure related to changes in beneficial ownership by a company insider. It doesn't provide specific insights into the broader pharmaceutical industry or competitive landscape.

Related Party Transactions

• Myron W. Shulgan acquired 100,000 ordinary shares from Drugs Made In America Acquisition LLC, the Issuer's sponsor.

Stakeholder Impact

• The acquisition of shares by a director could be perceived positively by shareholders as it demonstrates confidence in the company.

Key Dates

Keywords

ordinary shares, acquisition, director, DMAA, Drugs Made In America Acquisition Corp., beneficial ownership, Form 4, Shulgan, Myron W.